WHO backs remdesivir trial data after Gilead terms it inconsistent with 'robust evidence'

World Health Organisation (WHO) trial data on Gile Sciences Inc.'s experimental antiviral drug remdesivir is reliable, said an independent statistician hired by UN health ncy to evaluate Solidarity trial results. WHO anunced on October 15 that interim results from Solidarity rapeutics Trial indicate little or effect of remdesivir on 28-day mortality or in-hospital course of COVID-19 among hospitalized patients.

American biopharmaceutical company criticised UN ncy for releasing initial data prior to publication in a peer-reviewed journal. Gile Sciences said in a statement that emerging data appear inconsistent with “more robust evidence” from multiple randomized, controlled studies published in peer-reviewed journals validating clinical benefit of remdesivir.

“We are concerned that data from this open-label global trial have t undergone rigorous review required to allow for constructive scientific discussion, particularly given limitations of trial design,” statement re.

Re: Trump Receiving Remdesivir rapy For COVID-19; All About Unapproved Antibody Drug

Re: European Commission To Procure Remdesivir Drug Amid Short; Pens New Deal With Gile

'Real-world evidence'

Richard Peto, Professor of Medical Statistics and Epidemiology at University of Oxford, told reporters that result is reliable, calling it “real-world evidence”. statistician suggested company will try to contrict it, urging people to t believe such claims. WHO h earlier said that world’s largest randomized control trial on COVID-19 rapeutics has generated conclusive evidence on effectiveness of repurposed drugs for treatment of COVID-19.

“ study, which spans more than 30 countries, looked at effects of se treatments on overall mortality, initiation of ventilation, and duration of hospital stay in hospitalized patients,” WHO said in a statement.

In recognition of current public health emergency and based on available clinical data, approval status of drug varies from country to country. Last week, Gile Sciences and European Commission signed a joint procurement agreement (JPA) that would allow bloc to purchase an ditional 5,00,000 doses of remdesivir after several European countries said y are experiencing a short. 

Re: India Gives 3,000 Vials Of Remdesivir To 'friendly' Myanmar To Help Fight COVID-19

Re: Fnavis Flags Remdesivir Short In Maharashtra, Seeks Relief For Poor COVID-19 Patients

(Im: AP)